New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications


SMAD7 conditional knockout mice are available for licensing. SMAD7 can be knocked out by breeding with CRE-recombinase transgenic mice with a variety of promoters to yield tissue or cell type-specific deletions of SMAD7. SMAD7 has been shown to play a role in bone morphogenesis, cardiovascular tissue generation, immune regulation and fibrosis. Therefore, these mice provide a unique model to examine the role of the SMAD7 gene in disease processes that involve immunological, fibrotic, or cardiovascular components. Specifically, these mice may represent a novel model of Scleroderma, a disease with both an immunological and fibrotic component.

Potential Commercial Applications: Competitive Advantages:
  • Mouse model of Scleroderma
  • Means of studying bone morphogenesis and cardiovascular tissue generation
  • Means of studying the role of SMAD7 in immune regulation
 


Inventors:

Marilyn Diaz (NIEHS)  ➽ more inventions...


Intellectual Property:
Research Material -- patent protection is not being pursued for this technology

Publications:
Dong C, et al. PMID 11904440

Collaboration Opportunity:

The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Sally E. Tilotta, Ph.D. at sally.tilotta@nih.gov for more information.


Licensing Contact:
Uri Reichman, Ph.D., M.B.A.
Email: uri.reichman@nih.gov
Phone: 301-435-4616

OTT Reference No: E-040-2010-0
Updated: May 4, 2018